PureTech Health PLC - clinical-stage biotherapeutics company - Notes investee Akili Interactive has secured USD160 million of combined equity and debt financing. Says funding will accelerate commercialization of Akili's flagship treatment EndeavorRx, enable expansion of Akili's core technology to treat acute and chronic cognitive disorders, and drive further research and development of new technologies to treat broader range of conditions.
Current stock price: 378.50p
Year-to-date change: down 5.4%
By Arvind Bhunjun; arvindbhunjun@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
PureTech (PRTC)